艾瑞思姆科技

US · IRTC #2372 按市值排名上市于 2016

108.66 -0.69 -0.63%

实时 - 追踪5344个代码 - 心跳于46秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量增加了2家。
机构持股总比例下降了0.1个百分点。

机构持股

机构持股比例: 109.83% -0.12pp
机构数量: 376 +2
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund79.22%

Hedge Fund22.17%

Public Company4.41%

Private Company1.65%

Individual/Insider1.50%

Government Pension Fund0.87%

VC/PE Fund0.68%

Sovereign Wealth Fund0.45%

Insurance Company0.30%

主要股东截至 2026-06-30

BlackRock 9.06% · 2.99M 股

RTW Investments, LP 6.62% · 2.18M 股

Vanguard Portfolio Management, LLC 5.81% · 1.91M 股

Vanguard Capital Management, LLC 5.15% · 1.70M 股

Artisan Partners Limited Partnership 5.04% · 1.66M 股

Millennium Management LLC 4.27% · 1.41M 股

FMR 3.62% · 1.19M 股

UBS Asset Management 3.10% · 1.02M 股

Geode Capital Management, LLC 2.68% · 881.90K 股

Eventide Asset Management, LLC 2.67% · 880.34K 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 23次买入 · 26次卖出

姓名	职务	持股比例
Quentin Blackford	Chief Executive Officer	0.43%
Patrick Murphy	Chief Business & Legal Officer	0.21%
Sumi Shrishrimal	Executive Vice President	0.14%
Daniel Wilson	Executive VP of Corporate Development & Investor Relations	0.11%
Minang Turakhia	Chief Medical & Scientific Officer and Executive VP of Product Innovation	0.10%
Chad Patterson	Chief Commercial Officer	0.10%
Abhijit Talwalkar	Independent Chairperson	0.06%
Brian Lawrence	Executive Vice President	0.06%
Bruce Bodaken	Independent Director	0.04%
Mark Rubash	Independent Director	0.04%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-01	Daniel Wilson	Executive VP of Corporate Development & Investor Relations	Open Market Disposition	-773	$121.83
2026-08-09	Patrick Murphy	Chief Business & Legal Officer	Open Market Disposition	-7,093	$124.65
2026-08-09	Quentin Blackford	Chief Executive Officer	Open Market Disposition	-26,859	$124.65
2026-08-09	Minang Turakhia	Chief Medical & Scientific Officer and Executive VP of Product Innovation	Open Market Disposition	-7,093	$124.65
2026-08-09	Chad Patterson	Chief Commercial Officer	Open Market Disposition	-7,093	$124.65
2026-08-09	Sumi Shrishrimal	Executive Vice President	Open Market Disposition	-5,372	$124.65
2026-08-06	Patrick Murphy	Chief Business & Legal Officer	Other Acquisition	+13,589	--
2026-08-06	Quentin Blackford	Chief Executive Officer	Other Acquisition	+48,534	--
2026-08-06	Minang Turakhia	Chief Medical & Scientific Officer and Executive VP of Product Innovation	Other Acquisition	+13,589	--
2026-08-06	Chad Patterson	Chief Commercial Officer	Other Acquisition	+13,589	--
2026-08-06	Sumi Shrishrimal	Executive Vice President	Other Acquisition	+9,706	--
2026-08-02	Chad Patterson	Chief Commercial Officer	Open Market Disposition	-2,712	$122.12
2026-08-02	Mervin Smith	Executive Vice President of Strategic Business Operations	Open Market Disposition	-617	$122.12
2026-08-02	Julianne Rodda	--	Open Market Disposition	-2,112	$122.12
2026-07-01	Sean Freeman	Executive Vice President of Strategy & Corporate Development	Open Market Disposition	-918	$124.71
2026-07-01	Minang Turakhia	Chief Medical & Scientific Officer and Executive VP of Product Innovation	Open Market Disposition	-1,423	$124.71
2026-06-01	Marc Rosenbaum	Senior VP of Finance & Chief Accounting Officer	Open Market Disposition	-729	$108.19
2026-06-01	Sumi Shrishrimal	Executive Vice President	Open Market Disposition	-1,716	$108.19
2026-05-28	Quentin Blackford	Chief Executive Officer	Other Acquisition	+178	$96.82
2026-05-28	Sean Freeman	Executive Vice President of Strategy & Corporate Development	Other Acquisition	+273	$96.82

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。